News

USP opens new testing facility in India

US Pharmacopeial Convention  has opened a new expanded testing facility in the IKP Knowledge Park in Hyderabad, India. The new facility will allow voluntary testing and auditing program that helps dietary supplement manufacturers ensure and attest...

BioVigilant submits rapid biologic detection systems DMFs with FDA

BioVigilant has submitted Type V drug master files of IMD-A 300 series of rapid biologic detection systems to the US Federal Drug Administration.BioVigilant's IMD system is used to detect the presence of bacteria in the pharmaceutical manufacturing environments. ...

Mannatech adds vitamin D to omega-3 supplement

Mannatech, a developer and provider of nutritional supplements and skin care products based on Real Food Technology solutions, has added vitamin D to its omega-3 supplement. The new Omega-3 with Vitamin D3 capsules now comprise 830...

Isconova, Genocea widen licensing deal

Isconova and Genocea Biosciences have widened their existing agreement, under which Isconova has given license for using its Matrix M to Genocea Biosciences in vaccines targeting two additional diseases. Currently, Genocea has the right to...

Alto Pharma to introduce DermSafe hand sanitizer

Alto Pharmaceuticals is set to introduce Skinvisible Pharmaceuticals' DermSafe antimicrobial hand sanitizer in Canada on 1 September 2011.Under an agreement signed between both the companies, Skinvisible has given Canadian marketing rights of DermSafe to Alto. Alto...

SG Austria gets milestone payment

The Economic Development Board of Singapore has paid milestone payment to SG Austria, an affiliate of Nuvilex.The milestone was paid for achieving key scientific milestones following independent scientific review of the company's ongoing R&D projects. The...

Roche licenses vemurafenib to Chugai

F Hoffmann-La Roche has given marketing and development rights of BRAF inhibitor vemurafenib to Chugai Pharmaceutical. The licensing deal allows Roche to get milestone payments from Chugai Pharma.Chugai Pharma intends to begin a Phase I clinical...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read